# A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re

Source: https://onco.cc/trials/nct05519085/  
OnCo record `nct05519085` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Mezigdomide, Pomalidomide, Bortezomib in multiple myeloma, run by Celgene, now recruiting.

## Summary

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT05519085 by Celgene, with 810 participants planned, started 2022-09-20 and due to reach its primary completion in 2027-01-10. Interventions recorded: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05519085
- Phase: 3
- Setting: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
- Sponsor: Celgene
- Enrolled: 810

## Sources

- ClinicalTrials.gov NCT05519085: https://clinicaltrials.gov/study/NCT05519085

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Mezigdomide](https://onco.cc/drugs/mezigdomide/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05519085.json